EUVIMEDScopri EUVIMED
Multizentrische StudieOpen access · CC BY-NC-ND 4.0

Romiplostim for treatment of thrombocytopenia in dogs: A retrospective assessment and clinical outcomes

Min-Ok Ryu iD, Jin-Kyung Kim iD, Ju-Hyun An iD, Kyoung-Won Seo iD, Ye-In Oh iD, Hwa-Young Youn iD

Journal of Veterinary Internal Medicine · 2024

DOI: 10.1111/jvim.17131 ↗

At a glance

Multizentrische Studie in Journal of Veterinary Internal Medicine, 2024. Written by Min-Ok Ryu and 5 co-authors. Institution: Laboratory of Internal Medicine, Department of Veterinary Clinical Science, College of Veterinary Science and Research Institute for Veterinary Scien…. Major MEDLINE topics: Thrombopoietin, Receptors, Fc, Recombinant Fusion Proteins, Dog Diseases. Cited 6 times so far (Crossref); 13 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Background

Romiplostim, a thrombopoietin analog, is commonly used to treat immune-mediated thrombocytopenia (ITP) in humans, but its use in dogs remains limited.

Objectives

Evaluate the effects and adverse events of romiplostim administration in dogs with thrombocytopenia caused by various underlying diseases. Animals Forty-two client-owned dogs with naturally occurring thrombocytopenia at 2 referral animal hospitals.

Methods

Retrospective, multi-institutional analysis to evaluate the outcomes of romiplostim treatment in dogs.

Results

Among the dogs treated with romiplostim, 27 experienced an increase in platelet count and 26 maintained a platelet count within the reference range. Platelet count improvement was observed in various conditions: primary ITP (90%, n = 18/20), pancytopenia of unknown etiology (42.9%, n = 3/7), chemotherapy-induced thrombocytopenia (50%, n = 3/6), babesiosis (100%, n = 1/1), radiotherapy-induced thrombocytopenia (0%, n = 0/1), and disseminated intravascular coagulopathy (33.3%, n = 2/6). The median time for platelet recovery (>50 000/μL) after romiplostim administration was 4 days, and the median time for platelet count normalization was 7 days. Median hospitalization time for the improvement group (I) was 5 days. The survival-to-discharge rates were 85%, 40%, and 28.6% for dogs with primary ITP, secondary thrombocytopenia, and thrombocytopenia of unknown etiology, respectively. Conclusions and Clinical Importance Romiplostim is a well-tolerated and promising treatment for primary ITP in dogs, suggesting its potential as a valuable therapeutic option for dogs with thrombocytopenia caused by various underlying conditions. These findings emphasize the need for further research to optimize romiplostim dosing and understand its role in treating secondary thrombocytopenia and pancytopenia of unknown etiology.

Subjects

MeSH terms (MEDLINE)

ThrombopoietinReceptors, FcRecombinant Fusion ProteinsDog DiseasesThrombocytopeniaDogsAnimalsRetrospective StudiesFemaleMalePlatelet CountTreatment OutcomePurpura, Thrombocytopenic, Idiopathic

Author keywords

canineimmune‐mediatedpancytopeniathrombopoietin

Substances

romiplostimThrombopoietinReceptors, FcRecombinant Fusion Proteins

Authors and institutions

  • Laboratory of Internal Medicine, Department of Veterinary Clinical Science, College of Veterinary Science and Research Institute for Veterinary Science, Seoul National University, Seoul 08826, Republic of Korea.
  • Haemaru Companion Animal Medical Foundation, Seongnam, Republic of Korea.
  • Department of Veterinary Emergency and Critical Care Medicine and Institute of Veterinary Science, College of Veterinary Medicine, Kangwon National University, Chuncheon-si, Republic of Korea.
  • Department of Veterinary Internal Medicine, College of Veterinary Medicine & Institute for Veterinary Biomedical Science, Kyungpook National University, Daehakro 80, Daegu, Republic of Korea.

ORCID profiles: Min-Ok Ryu, Jin-Kyung Kim, Ju-Hyun An, Kyoung-Won Seo, Ye-In Oh, Hwa-Young Youn

Cite

APA

Ryu, M. O., Kim, J. K., An, J. H., Seo, K. W., Oh, Y. I., & Youn, H. Y. (2024). Romiplostim for treatment of thrombocytopenia in dogs: A retrospective assessment and clinical outcomes. Journal of Veterinary Internal Medicine. https://doi.org/10.1111/jvim.17131

Vancouver

Ryu MO, Kim JK, An JH, Seo KW, Oh YI, Youn HY. Romiplostim for treatment of thrombocytopenia in dogs: A retrospective assessment and clinical outcomes. Journal of Veterinary Internal Medicine. 2024. doi:10.1111/jvim.17131

BibTeX
@article{Ryu2024,
  author = {Ryu, Min-Ok and Kim, Jin-Kyung and An, Ju-Hyun and Seo, Kyoung-Won and Oh, Ye-In and Youn, Hwa-Young},
  title = {Romiplostim for treatment of thrombocytopenia in dogs: A retrospective assessment and clinical outcomes},
  journal = {Journal of Veterinary Internal Medicine},
  year = {2024},
  doi = {10.1111/jvim.17131}
}
Start for free →